Area of research
Hematology · Genetics
Research interest
Research interests include Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, and Eosinophilic Disorders and Syndromes.
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery
Advancing the Integration of ‘Basic/Fundamental’ and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison
Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT
The role of registries in hematological disorders
Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of <scp>EBMT</scp> and the Spanish Myelofibrosis Registry
Patients with triple-negative, <i>JAK2</i>V617F- and <i>CALR</i>-mutated essential thrombocythemia share a unique gene expression signature
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT
Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms
Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of <scp>EBMT</scp>
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment